Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Expands By 264.5%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 572,600 shares, an increase of 264.5% from the January 15th total of 157,100 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 55.1% of the company’s shares are sold short.

CERo Therapeutics Price Performance

Shares of CERO stock traded down $0.01 on Thursday, reaching $1.80. 15,375 shares of the company’s stock were exchanged, compared to its average volume of 983,302. CERo Therapeutics has a 52 week low of $1.70 and a 52 week high of $1,238.00. The company’s fifty day simple moving average is $4.59 and its 200 day simple moving average is $10.00.

Insider Transactions at CERo Therapeutics

In other news, major shareholder Bioventures Opportunities G. Yk sold 29,989 shares of CERo Therapeutics stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.00, for a total value of $179,934.00. Following the completion of the transaction, the insider now owns 130,051 shares in the company, valued at approximately $780,306. The trade was a 18.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders sold 64,300 shares of company stock worth $529,409. 18.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CERo Therapeutics

An institutional investor recently raised its position in CERo Therapeutics stock. Avantax Planning Partners Inc. raised its position in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 89.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,585,151 shares of the company’s stock after purchasing an additional 1,224,021 shares during the period. Avantax Planning Partners Inc. owned about 172.00% of CERo Therapeutics worth $155,000 as of its most recent filing with the Securities & Exchange Commission. 29.64% of the stock is currently owned by institutional investors.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.